Current controversies in Crohn's disease: A roundtable discussion of the BRIDGe group

Gastroenterology and Hepatology

Volumn 4, Issue 10, 2008, Pages 713-720

  Sparrow, Miles P ^a,l   Irving, Peter M ^b   Baidoo, Leonard ^c   Bressler, Brian ^d   Cheifetz, Adam S ^e   Devlin, Shane M ^f   Harrell, Laura E ^g   Jones, Jennifer ^f   Kozuch, Patricia L ^h   Melmed, Gil Y ⁱ   Velayos, Fernando S ^j   Siegel, Corey A ^k  

^a MONASH UNIVERSITY   (Australia)

^b BASILDON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF CHICAGO   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^l BOX HILL HOSPITAL   (Australia)

more..

Author keywords

5 aminosalicylates; Biologic therapies; Crohn's disease; Immunomodulators; Inflammatory bowel disease

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE;

AUSTRALIA; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CROHN DISEASE; DEMYELINATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; INFECTION RISK; MEDICAL EDUCATION; META ANALYSIS; MONOTHERAPY; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; RELAPSE; REMISSION; SIDE EFFECT; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES;

EID: 54149109148     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, et al. National cooperative Crohns disease study: results of drug treatment. Gastroenterology. 1979;77(4 pt 2):847-869.
2. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993;104:1293-1301.
3. Nordic Research Inc. Clinical research report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's II).
4. Hoechst Marion Roussel Inc. Clinical study report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's III).
5. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379-388.
6. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2005;(1):CD003715.
7. Cammà C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-1473.
8. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
9. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346-1350.
10. Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis. 2006;12:491-496.
11. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
12. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
13. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
14. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
15. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
16. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
17. Schreiber S, Khaliq-Kareemi M, Lawrence IC, Thomsen OØ, Hanauer SB, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
18. Feagan BG, McDonald JW, Panaccione R. Combination of maintenance methotrexate-infliximab trial. Gastroenterology. 2008;135:294-295.
19. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
20. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
21. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
22. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241.
23. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
24. Siegel CA. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology. 2008;134(suppl 1):A-144.
25. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
26. D'Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
27. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442; quiz 464.
28. Frøslie KF, Jahnsen J, Mourn BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
29. Baert FJ, Moortgat L, Van Assche GA, Caenepeel P, Vergauwe PL, et al. Mucosal healing predicts sustained clinical remission in early Crohn's disease. Gastroenterology. 2008;134(suppl 1):A-640.
30. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
31. Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, et al. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl. 2006:46-54.
32. Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13:2028-2036.
33. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
34. Cho JH. Significant role of genetics in IBD: the NOD2 gene. Rev Gastroenterol Disord. 2003;3(suppl 1):S18-S22.